clearside
biomedical
oncology
licensing
partner
doses
first
patient
phase
study
patients
choroidal
melanoma
using
scs
suprachoroidal
delivery
alpharetta
globe
newswire
clearside
biomedical
nasdaq
clsd
biopharmaceutical
company
dedicated
developing
delivering
treatments
restore
preserve
vision
people
serious
back
eye
diseases
announced
today
licensing
partner
aura
biosciences
dosed
first
patient
phase
clinical
trial
evaluating
safety
efficacy
suprachoroidal
administration
potential
treatment
patients
primary
choroidal
melanoma
aura
using
clearside
scs
deliver
suprachoroidal
space
aura
also
announced
passed
safety
review
first
dose
escalation
cohort
demonstrated
favorable
safety
data
safety
findings
adverse
events
noted
aura
preclinical
data
suprachoroidal
injection
presented
association
research
vision
ophthalmology
conference
accessed
trial
initiation
track
three
product
candidates
delivered
via
scs
microinjector
four
clinical
trials
year
said
thomas
ciulla
mba
chief
medical
officer
chief
development
officer
choroidal
melanoma
rare
aggressive
type
eye
cancer
common
primary
intraocular
tumor
adults
aura
leader
field
unmet
need
new
treatment
option
early
stage
choroidal
melanoma
excited
ocular
oncologists
interest
suprachoroidal
delivery
look
forward
aura
continued
clearside
scs
clearside
patented
proprietary
suprachoroidal
space
injection
treatment
approach
offers
unprecedented
access
back
eye
disease
often
occurs
clearside
proprietary
scs
used
inject
wide
variety
drug
candidates
specifically
formulated
delivered
via
suprachoroidal
injection
scs
microinjector
provides
targeted
delivery
potentially
improve
efficacy
compartmentalization
medication
reduce
eliminate
toxic
effects
cells
scs
microinjector
composed
syringe
two
hollow
microneedles
varying
lengths
less
millimeters
within
hub
optimizes
insertion
suprachoroidal
administration
drugs
clearside
biomedical
clearside
biomedical
biopharmaceutical
company
dedicated
developing
delivering
treatments
restore
preserve
vision
people
serious
back
eye
diseases
clearside
proprietary
scs
targets
suprachoroidal
space
offers
unique
access
macula
retina
choroid
disease
often
occurs
company
scs
injection
platform
inherently
flexible
procedure
intended
provide
targeted
delivery
site
disease
work
established
new
formulations
medications
well
future
therapeutic
innovations
gene
therapy
information
please
visit
cautionary
note
regarding
statements
statements
contained
press
release
describe
historical
facts
may
constitute
statements
term
defined
private
securities
litigation
reform
act
statements
may
identified
words
believe
expect
may
plan
potential
similar
expressions
based
clearside
current
beliefs
expectations
statements
include
statements
regarding
clinical
development
potential
benefits
therapies
using
clearside
scs
timing
data
presentations
clearside
licensing
partner
statements
involve
risks
uncertainties
could
cause
actual
results
differ
materially
reflected
statements
risks
uncertainties
may
cause
actual
results
differ
materially
include
uncertainties
inherent
conduct
clinical
trials
clearside
reliance
third
parties
may
always
full
control
uncertainties
regarding
pandemic
risks
uncertainties
described
clearside
annual
report
form
year
ended
december
filed
securities
exchange
commission
sec
march
clearside
quarterly
report
form
quarter
ended
june
filed
sec
august
clearside
periodic
reports
filed
sec
statements
speak
date
press
release
based
information
available
clearside
date
release
clearside
assumes
obligation
intend
update
statements
whether
result
new
information
future
events
otherwise
investor
media
contacts
jenny
kobin
remy
bernarda
ir
source
clearside
biomedical
inc
